These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 9798060)

  • 1. Precipitous declines in hemoglobin levels associated with combination zidovudine and lamivudine therapy.
    Tseng A; Conly J; Fletcher D; Keystone D; Salit I; Walmsley S
    Clin Infect Dis; 1998 Oct; 27(4):908-9. PubMed ID: 9798060
    [No Abstract]   [Full Text] [Related]  

  • 2. Profound and unanticipated anemia with lamivudine-zidovudine combination therapy in zidovudine-experienced patients with HIV infection.
    Hester EK; Peacock JE
    AIDS; 1998 Mar; 12(4):439-40. PubMed ID: 9520175
    [No Abstract]   [Full Text] [Related]  

  • 3. Tolerability of postexposure prophylaxis with zidovudine, lamivudine, and nelfinavir for human immunodeficiency virus infection.
    Rabaud C; Bevilacqua S; Beguinot I; Dorvaux V; Schuhmacher H; May T; Canton P
    Clin Infect Dis; 2001 May; 32(10):1494-5. PubMed ID: 11317252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Triple nuke therapy--results after one year.
    TreatmentUpdate; 2001; 12(10):3-4. PubMed ID: 11570063
    [No Abstract]   [Full Text] [Related]  

  • 5. Zidovudine + lamivudine: new preparation. Fewer tablets required.
    Prescrire Int; 1999 Apr; 8(40):39-40. PubMed ID: 10848057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiretroviral rounds. When success is a pain.
    Bartlett JG; del Rio C
    AIDS Clin Care; 2001 Aug; 13(8):74-5. PubMed ID: 11547461
    [No Abstract]   [Full Text] [Related]  

  • 7. Special issue on health risks of perinatal exposure to nucleoside reverse transcriptase inhibitors.
    Walker VE; Poirier MC
    Environ Mol Mutagen; 2007; 48(3-4):159-65. PubMed ID: 17358025
    [No Abstract]   [Full Text] [Related]  

  • 8. Mitochondrial and peroxisomal dysfunction following perinatal exposure to antiretroviral drugs.
    Stojanov S; Wintergerst U; Belohradsky BH; Rolinski B
    AIDS; 2000 Jul; 14(11):1669. PubMed ID: 10983660
    [No Abstract]   [Full Text] [Related]  

  • 9. Severe anoxic hepatic necrosis in an HIV-1-hepatitis C virus-co-infected patient starting antiretroviral triple combination therapy.
    Karras A; Rabian C; Zylberberg H; Hermine O; Duchatelle V; Durand F; Valla D; Viard JP
    AIDS; 1998 May; 12(7):827-9. PubMed ID: 9619823
    [No Abstract]   [Full Text] [Related]  

  • 10. AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients.
    AIDS; 2000 Mar; 14(4):367-74. PubMed ID: 10770538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spontaneous recovery of hemoglobin and neutrophil levels in Japanese patients on a long-term Combivir containing regimen.
    Matsushita S; Yoshimura K; Kimura T; Kamihira A; Takano M; Eto K; Shirasaka T; Mitsuya H; Oka S
    J Clin Virol; 2005 Jul; 33(3):188-93. PubMed ID: 15911439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lactic acid levels in children perinatally treated with antiretroviral agents to prevent HIV transmission.
    Giaquinto C; De Romeo A; Giacomet V; Rampon O; Ruga E; Burlina A; De Rossi A; Sturkenboom M; D'Elia R
    AIDS; 2001 May; 15(8):1074-5. PubMed ID: 11399997
    [No Abstract]   [Full Text] [Related]  

  • 13. Severe anemia as a newly recognized side-effect caused by lamivudine.
    Weitzel T; Plettenberg A; Albrecht D; Lorenzen T; Stoehr A
    AIDS; 1999 Nov; 13(16):2309-11. PubMed ID: 10563721
    [No Abstract]   [Full Text] [Related]  

  • 14. 144-week data released on Gilead's study 934.
    AIDS Patient Care STDS; 2007 Aug; 21(8):603-4. PubMed ID: 17902243
    [No Abstract]   [Full Text] [Related]  

  • 15. Mitigation of hepato-cellular injury caused by HAART with glycyrrhizin compound in patients co-infected with HIV and HCV.
    Yamamoto Y; Yasuoka A; Tachikawa N; Teruya K; Genka I; Yamaguchi M; Yasuoka C; Kikuchi Y; Aoki M; Oka S
    Jpn J Infect Dis; 1999 Dec; 52(6):248-9. PubMed ID: 10738365
    [No Abstract]   [Full Text] [Related]  

  • 16. A new HAART on the horizon says the proof is in the potency.
    AIDS Alert; 1999 Apr; 14(4):37-9. PubMed ID: 11366218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.
    Hammer SM; Squires KE; Hughes MD; Grimes JM; Demeter LM; Currier JS; Eron JJ; Feinberg JE; Balfour HH; Deyton LR; Chodakewitz JA; Fischl MA
    N Engl J Med; 1997 Sep; 337(11):725-33. PubMed ID: 9287227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-HIV agents. Abacavir--as good as AZT?
    TreatmentUpdate; 2003 Oct; 15(6):3-4. PubMed ID: 17216861
    [No Abstract]   [Full Text] [Related]  

  • 19. Phase II study of vicriviroc versus efavirenz (both with zidovudine/lamivudine) in treatment-naive subjects with HIV-1 infection.
    Landovitz RJ; Angel JB; Hoffmann C; Horst H; Opravil M; Long J; Greaves W; Fätkenheuer G
    J Infect Dis; 2008 Oct; 198(8):1113-22. PubMed ID: 18783318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Geotrichum proctitis after HIV postexposure prophylaxis.
    Yánez L; Hernández JL; Saiz N; Calvo J; Ramos C; Salesa R; González-Macías J
    AIDS; 2002 Aug; 16(12):1701-2. PubMed ID: 12172101
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.